TriangleSutetinib Maleate Capsule (NCT05168566)
Sutetinib Maleate Capsule trial for Non-small Cell Lung Cancer (NCT05168566). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced or metastatic non-small cell lung cancer containing one or more of the EGFR mutations L861Q, G719X or S768I. Other sensitizing EGFR changes or oncogenic drivers are excluded. No previous EGFR-inhibitor treatment and no more than one chemotherapy line are allowed.
The idea: take sutetinib maleate capsules once daily. Sutetinib blocks EGFR signaling that supports cancer-cell growth. Researchers assess tumor response and safety; active brain metastases exclude participation.
This phase 2 study plans 128 patients. Teligene US sponsors six recruiting US locations.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.